The importance of long-term data in multiple sclerosis Xavier Montalban OriginalPaper Pages: vi9 - vi15
Neutralising antibodies to interferon-β–measurement, clinical relevance, and management Per Soelberg Sørensen OriginalPaper Pages: vi16 - vi22
Assessing long-term effects of disease-modifying drugs Bernd C. Kieseier OriginalPaper Pages: vi23 - vi30
Long-term experience with current disease-modifying drugs in multiple sclerosis Corey C. Ford OriginalPaper Pages: vi37 - vi44
Rationale and experience with combination therapies in multiple sclerosis Mike Boggild OriginalPaper Pages: vi45 - vi51